Skip to main content
. 2019 Jan 2;294(8):2628–2641. doi: 10.1074/jbc.RA118.005477

Figure 7.

Figure 7.

TPG-1 significantly suppressed the oncogenic capability of HepG2 cells in vivo without obvious side effects. A, nude mice bearing HepG2 tumor xenografts were treated with TPG-1 (i.p., 60 mg/kg, once daily) or 5-FU (i.p., 30 mg/kg, three times per week). B, body weight of the nude mice during drug treatment. C, H&E staining of major organs from nude mice treated with or without TPG-1. Scale bar, 50 μm. D–F, number of white blood cells, red blood cells, and blood platelets from nude mice treated with or without TPG-1. G, serum level of TNFα in nude mice treated with or without TPG-1 was measured by ELISA. H, H&E staining and immunohistochemical analysis of tumor tissues from nude mice treated with or without TPG-1. Scale bar, 50 μm (top) or 200 μm (bottom). *, p < 0.05; **, p < 0.01; ***, p < 0.001. Error bars, confidence interval.